Kurmi Balak Das, Tekchandani Pawan, Paliwal Rishi, Paliwal Shivani Rai
Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, CG. India.
Columbia Institute of Pharmacy, Raipur, CG. India.
Curr Drug Metab. 2017;18(5):481-495. doi: 10.2174/1389200218666170222150555.
BACKGROUND: Transdermal drug delivery represents an extremely attractive and innovative route across the skin owing to the possibility for achieving systemic effect of drugs. The present scenario demands a special focus on developing safe medicine with minimized toxic adverse effects related to most of the pharmacologically active agents. Transdermal drug delivery would be a focal paradigm which provides patient convenience, first-pass hepatic metabolism avoidance, local targeting and reduction in toxic effect related to various categories of drugs like, analgesics, antiinflammatory, antibiotics, antiviral, anaesthetic, anticancer etc. Even this route has challenges due to highly organized structure of skin which acts as a main barrier to penetration of drug via the skin. METHOD: Several alternative possible strategies are available which overcome these barriers, including use of penetration enhancer, eletroporation, iontophoresis and various nanotechnologically developed nanocarrier systems. The latest one includes employing liposome, dendrimers, nanoparticles, ethosome, carbon nanotube and many more to avoid associated limitations of conventional formulations. Numerous transdermal products such as Estrasorb, Diractin, VivaGel®, Daytrana®, Aczone, Sileryst® are available in the market having a novel strategy to achieve higher penetration of drugs. This encourages formulation fraternity to develop structurally deformable and stable nanocarriers as an alternative approach for controlled and reliable drug delivery across the skin barrier. DISCUSSION: In this review, we will discuss nanocarriers mediated approaches that come-up with the solutions to the different challenges towards transdermal drug delivery, its clinical importance and latest insight to research in it. CONCLUSION: The reports presented in this review confirm the wide application of nanocarriers for transdermal delivery of drug/gene.
背景:由于有可能实现药物的全身效应,经皮给药是一种极具吸引力和创新性的皮肤给药途径。当前的情况需要特别关注开发安全的药物,尽量减少与大多数药理活性剂相关的毒性不良反应。经皮给药将是一个重点范例,它为患者提供便利,避免首过肝代谢,实现局部靶向,并减少与各类药物(如镇痛药、抗炎药、抗生素、抗病毒药、麻醉药、抗癌药等)相关的毒性作用。即便如此,由于皮肤高度有序的结构会对药物经皮渗透形成主要屏障,这条途径仍存在挑战。 方法:有几种可供选择的策略可以克服这些障碍,包括使用渗透促进剂、电穿孔、离子导入以及各种纳米技术开发的纳米载体系统。最新的一种包括使用脂质体、树枝状大分子、纳米颗粒、醇质体、碳纳米管等等,以避免传统制剂的相关局限性。市场上有许多经皮产品,如Estrasorb、Diractin、VivaGel®、Daytrana®、Aczone、Sileryst®,它们采用新颖的策略来实现更高的药物渗透。这促使制剂界开发结构可变形且稳定的纳米载体,作为一种跨越皮肤屏障进行可控且可靠药物递送的替代方法。 讨论:在本综述中,我们将讨论纳米载体介导的方法,这些方法为经皮给药面临的不同挑战提供了解决方案、其临床重要性以及该领域的最新研究见解。 结论:本综述中呈现的报告证实了纳米载体在药物/基因经皮递送方面的广泛应用。
Curr Drug Metab. 2017
Drug Deliv. 2016
J Control Release. 2022-11
Adv Drug Deliv Rev. 2018-2-6
Molecules. 2021-5-21
Pharmaceutics. 2025-8-15
ACS Pharmacol Transl Sci. 2025-5-24
Naunyn Schmiedebergs Arch Pharmacol. 2025-4-25
Recent Pat Nanotechnol. 2025
Adv Pharm Bull. 2023-11
Biomimetics (Basel). 2023-7-6
Pharmaceuticals (Basel). 2023-5-23